Faced with a dilem­ma, the FDA re­jects Cem­pra's an­tibi­ot­ic, de­mands big safe­ty study

Cem­pra de­liv­ered the FDA’s de­ci­sion on its an­tibi­ot­ic solithromycin on Thurs­day morn­ing, a day late and about $185 mil­lion short.

Caught on the horns of a dilem­ma posed by clear ev­i­dence of liv­er tox­i­c­i­ty and a grow­ing de­mand for new an­tibi­otics, the FDA has de­cid­ed to re­ject Cem­pra’s new an­tibi­ot­ic, de­mand­ing a large new safe­ty study be­fore re­con­sid­er­ing its po­si­tion. And the agency flagged a warn­ing that any fu­ture la­bel will care­ful­ly re­strict its use, which will dam­age its mar­ket po­ten­tial.

Cem­pra’s stock plunged 57% by the end of the day, wip­ing out about $185 mil­lion in mar­ket cap as in­vestors re­spond­ed to the worst sce­nario the biotech could have ex­pect­ed.

In a de­tailed out­line of the FDA’s CRL, Cem­pra not­ed that the agency was un­sat­is­fied by the rel­a­tive­ly small num­ber of pa­tients that had been re­cruit­ed to de­ter­mine how safe the an­tibi­ot­ic is. Reg­u­la­tors want them to aug­ment that with a study in­volv­ing 9,000 pa­tients. Cem­pra added:

The CRL not­ed that while the FDA re­serves com­ment on the pro­posed la­bel­ing un­til the NDAs are oth­er­wise ad­e­quate, even in the ab­sence of a case of Hy’s Law or of an­oth­er form of se­ri­ous DILI in fu­ture stud­ies, la­bel­ing will need to in­clude ad­e­quate in­for­ma­tion about the po­ten­tial for he­pa­to­tox­i­c­i­ty, lim­it­ing use to pa­tients who have lim­it­ed ther­a­peu­tic op­tions and lim­i­ta­tions re­gard­ing du­ra­tion of ther­a­py. A com­pre­hen­sive plan for post-mar­ket­ing safe­ty as­sess­ment in­clud­ing an en­hanced phar­ma­covig­i­lance pro­gram would al­so be re­quired.

Reg­u­la­tors al­so cit­ed man­u­fac­tur­ing is­sues in the CRL.

Cem­pra $CEMP faced a big chal­lenge go­ing in­to to­day’s an­nounce­ment. An ex­pert pan­el had of­fered its mar­gin­al sup­port with a 7-to-6 vote in fa­vor of an ap­proval. But they spent much of the day fret­ting over clear signs of tox­i­c­i­ty, which were al­so flagged in the agency’s in­ter­nal re­view. The main ques­tion at the end of the day was whether the FDA would ap­prove the an­tibi­ot­ic and then place a se­ries of pos­si­ble mar­ket-killing re­stric­tions on it or sim­ply re­ject it un­til they could get a bet­ter safe­ty pro­file.

Both the FDA and the pan­el, though, had to bal­ance their very re­al safe­ty con­cerns against a grow­ing need for new an­tibi­otics in an age of ris­ing drug re­sis­tance.

Cem­pra kept the mar­ket wait­ing for the bad news. The com­pa­ny faced two PDU­FA dates for their an­tibi­ot­ic’s oral and IV for­mu­la­tions on Tues­day and Wednes­day. The late news on the dou­ble re­jec­tion fol­lowed by the de­mand for a new tri­al and fu­ture re­stric­tions was enough to leave some an­a­lysts won­der­ing if this ther­a­py has any fu­ture at all. From Baird’s Bri­an Sko­r­ney:

At this point, we don’t see how Cem­pra moves for­ward with solithrom­cyin. The cost of run­ning a 9,000 pa­tient study with­out rev­enues from the drug to help sup­port the burn will be ex­treme­ly bur­den­some. De­spite hav­ing ~$225M in cash now, the av­er­age R&D burn in 2014-2015 was be­tween $15M and $20M per quar­ter when the Phase 3 stud­ies were be­ing run, and that’s on­ly in one-tenth the num­ber of pa­tients the FDA is ask­ing for. Fur­ther, even if ap­proved, se­vere la­bel­ing would like­ly de­ter physi­cians from us­ing it in the broad, front-line macrolide set­ting Cem­pra was hop­ing for. As a re­sult, we are low­er­ing our price tar­get to $2 on low­er prob­a­bil­i­ty of suc­cess and high­er cash burn.

Solithromycin is de­signed to work by med­dling with bac­te­r­i­al pro­tein syn­the­sis. And with a large num­ber of com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia pa­tients (CABP) re­sis­tant to the lead­ing an­tibi­ot­ic on the mar­ket, the Chapel Hill, NC-based biotech has won close at­ten­tion for its re­search work.

Cem­pra is one of just a few small biotechs which have been ad­vanc­ing late-stage an­tibi­otics in the pipeline. Nabri­va, Achao­gen and Paratek are three more play­ers in this field, while Big Phar­ma large­ly re­mains leery of a sec­tor well known for high risks and mar­gin­al pay­offs. To­day’s re­jec­tion leaves dwin­dling near-term shots at adding to the num­ber of an­tibi­otics avail­able to the pub­lic.

Illustration: Assistant Editor Kathy Wong for Endpoints News

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls



Talk therapy didn’t help Lily with attention deficit hyperactivity disorder, or ADHD. But a video game did.

As the 10-year-old zooms through icy waters and targets flying creatures on the snow-capped planet Frigidus, she builds attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She’s now less anxious and scattered, allowing her to stay on a low dose of ADHD medication, according to her mom Violet Vu.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

In the unblinded 148-person study, Eli Lilly pitted its drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare coverage outside of clinical trials. Notably, the study didn’t look at clinical outcomes, but rather the clearance of amyloid, a protein whose buildup is associated with Alzheimer’s disease, in the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Matt Gline, Roivant Sciences CEO (Photo by John Sciulli/Getty Images for GLG)

Pfiz­er and Roivant team up again for an­oth­er 'Van­t', set­ting up an­ti-in­flam­ma­to­ry show­down with Prometheus

Pfizer and Roivant are teaming up to launch a new ‘Vant’ aimed at bringing a mid-stage anti-inflammatory drug to market, the pair announced Thursday.

There’s no name for the startup yet, nor are there any employees. Thus far, the new company and Roivant can be considered “one and the same,” Roivant CEO Matt Gline tells Endpoints News. But Pfizer is so enthusiastic about the target that it elected to keep 25% of equity in the drug rather than take upfront cash from Roivant, Gline said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Roche HQ in Basel, Switzerland. (Image credit: Kyle LaHucik/Endpoints News)

As com­peti­tors near FDA goal­post, Roche spells out its re­peat Alzheimer's set­back

Before Roche can turn all eyes on a new version of its more-than-once-failed Alzheimer’s drug gantenerumab, the Big Pharma had to flesh out data on the November topline failure at an annual conference buzzier than in years past thanks to hotly watched rivals in the field: Eisai and Biogen’s lecanemab, and Eli Lilly’s donanemab.

There was less than a 10% difference between Roche’s drug and placebo at slowing cognitive decline across two Phase III trials, which combined enrolled nearly 2,000 Alzheimer’s patients. In its presentation at the conference Wednesday, Roche said it saw less sweeping away of toxic proteins than it had anticipated. For years, researchers and investors have put their resources behind the idea that more amyloid removal would equate to reduced cognitive decline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

SQZ Biotech slash­es head­count by 60% as founder/CEO hits ex­it — while Syn­log­ic lays off 25%

It’s a tough time for early-stage companies developing highly promising, but largely unproven, new technologies.

Just ask SQZ Biotechnologies and Synlogic. The former is bidding farewell to its founder and CEO and slashing the headcount by 60% as it pivots from its original cell therapy platform to a next-gen approach; the latter — a synthetic biology play founded by MIT’s Jim Collins and Tim Lu — is similarly “optimizing” the company to focus on lead programs. The resulting realignment means 25% of the staffers will be laid off.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Lynn Baxter, Viiv Healthcare's head of North America

Vi­iV dri­ves new cor­po­rate coali­tion in­clud­ing Uber, Tin­der and Wal­mart, aimed at end­ing HIV

ViiV Healthcare is pulling together an eclectic coalition of consumer businesses in a new White House-endorsed effort to end HIV by the end of the decade.

The new US Business Action to End HIV includes pharma and health companies — Gilead Sciences, CVS Health and Walgreens — but extends to a wide range of consumer companies that includes Tinder, Uber and Walmart.

ViiV is the catalyst for the group, plunking down more than half a million dollars in seed money and taking on ringmaster duties for launch today on World AIDS Day, but co-creator Health Action Alliance will organize joint activities going forward. ViiV and the alliance want and expect more companies to not only join the effort, but also pitch in funding.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting: